Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Tourmaline Bio (TRML – Research Report) and keeping the price target at $50.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Tourmaline Bio’s lead product candidate, TOUR006. The company’s ongoing Phase II trials for Pacibekitug suggest that the drug could offer a differentiated profile compared to its main competitor, Ziltivekimab, particularly with its Q3M dosing regimen. This differentiation is expected to result in a superior efficacy profile, potentially establishing TOUR006 as a best-in-class treatment in the IL-6 space.
Moreover, the anticipated Phase II data could position Tourmaline Bio strategically in the ASCVD market, where IL-6 is a less crowded target. The potential for TOUR006 to deliver a more attractive profile than its competitors, combined with its strategic development informed by ZEUS trial results, enhances its appeal. These factors contribute to the expectation of significant upside potential for TRML, justifying the Buy rating from Biliouris.
In another report released on March 14, Leerink Partners also maintained a Buy rating on the stock with a $49.00 price target.